Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSPECT: Tirzepatide to Prevent Early-onset Colorectal Tumors
NCT07095517Phase 1Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2026
- Primary completion
- Mar 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tirzepatide in colorectal cancer (CRC) and Colorectal Adenoma (CRA), sponsored by Massachusetts General Hospital. Primary endpoint: Change in Urinary PGE-M at 24 weeks. Started Feb 2026; status: recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)Colorectal Adenoma (CRA)
Beyond the preview
Go deeper on NCT07095517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07095517.